These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

388 related items for PubMed ID: 1692251

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Evaluation of ricin A chain-containing immunotoxins directed against the CD30 antigen as potential reagents for the treatment of Hodgkin's disease.
    Engert A, Burrows F, Jung W, Tazzari PL, Stein H, Pfreundschuh M, Diehl V, Thorpe P.
    Cancer Res; 1990 Jan 01; 50(1):84-8. PubMed ID: 2152774
    [Abstract] [Full Text] [Related]

  • 3. Antitumor activity of Fab' and IgG-anti-CD22 immunotoxins in disseminated human B lymphoma grown in mice with severe combined immunodeficiency disease: effect on tumor cells in extranodal sites.
    Ghetie MA, Richardson J, Tucker T, Jones D, Uhr JW, Vitetta ES.
    Cancer Res; 1991 Nov 01; 51(21):5876-80. PubMed ID: 1933855
    [Abstract] [Full Text] [Related]

  • 4. Evaluation of ricin A chain-containing immunotoxins directed against CD19 and CD22 antigens on normal and malignant human B-cells as potential reagents for in vivo therapy.
    Ghetie MA, May RD, Till M, Uhr JW, Ghetie V, Knowles PP, Relf M, Brown A, Wallace PM, Janossy G.
    Cancer Res; 1988 May 01; 48(9):2610-7. PubMed ID: 2451562
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Development of new ricin A-chain immunotoxins with potent anti-tumor effects against human Hodgkin cells in vitro and disseminated Hodgkin tumors in SCID mice using high-affinity monoclonal antibodies directed against the CD30 antigen.
    Schnell R, Linnartz C, Katouzi AA, Schön G, Bohlen H, Horn-Lohrens O, Parwaresch RM, Lange H, Diehl V, Lemke H.
    Int J Cancer; 1995 Oct 09; 63(2):238-44. PubMed ID: 7591211
    [Abstract] [Full Text] [Related]

  • 9. A Phase I study with an anti-CD30 ricin A-chain immunotoxin (Ki-4.dgA) in patients with refractory CD30+ Hodgkin's and non-Hodgkin's lymphoma.
    Schnell R, Staak O, Borchmann P, Schwartz C, Matthey B, Hansen H, Schindler J, Ghetie V, Vitetta ES, Diehl V, Engert A.
    Clin Cancer Res; 2002 Jun 09; 8(6):1779-86. PubMed ID: 12060617
    [Abstract] [Full Text] [Related]

  • 10. Identification of an Mr 70,000 antigen associated with Reed-Sternberg cells and interdigitating reticulum cells.
    Hsu PL, Hsu SM.
    Cancer Res; 1990 Jan 15; 50(2):350-7. PubMed ID: 2153049
    [Abstract] [Full Text] [Related]

  • 11. Efficient transplantation of human non-T-leukemia cells into nude mice and induction of complete regression of the transplanted distinct tumors by ricin A-chain conjugates of monoclonal antibodies SN5 and SN6.
    Hara H, Luo Y, Haruta Y, Seon BK.
    Cancer Res; 1988 Aug 15; 48(16):4673-80. PubMed ID: 2969282
    [Abstract] [Full Text] [Related]

  • 12. Experimental treatment of human Hodgkin's disease with ricin A-chain immunotoxins.
    Engert A, Gottstein C, Winkler U, Amlot P, Pileri S, Diehl V, Thorpe P.
    Leuk Lymphoma; 1994 May 15; 13(5-6):441-8. PubMed ID: 8069189
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Idiotype vaccine against Hodgkin's lymphoma: generation and characterization of an anti-idiotypic monoclonal antibody against the Hodgkin-associated (anti-CD 30) monoclonal antibody HRS-3.
    Pohl C, Sieber M, Diehl V, Pfreundschuh M.
    Anticancer Res; 1991 May 15; 11(3):1115-24. PubMed ID: 1653553
    [Abstract] [Full Text] [Related]

  • 15. Pharmacokinetics of tumor-reactive immunotoxins in tumor-bearing mice: effect of antibody valency and deglycosylation of the ricin A chain on clearance and tumor localization.
    Fulton RJ, Tucker TF, Vitetta ES, Uhr JW.
    Cancer Res; 1988 May 01; 48(9):2618-25. PubMed ID: 3258546
    [Abstract] [Full Text] [Related]

  • 16. Improved antitumor effects of immunotoxins prepared with deglycosylated ricin A-chain and hindered disulfide linkages.
    Thorpe PE, Wallace PM, Knowles PP, Relf MG, Brown AN, Watson GJ, Blakey DC, Newell DR.
    Cancer Res; 1988 Nov 15; 48(22):6396-403. PubMed ID: 3263186
    [Abstract] [Full Text] [Related]

  • 17. Inhibition of the helper function of murine T cells with Fab'-anti-L3T4 ricin A chain immunotoxin.
    Street NE, Fulton RJ, Sanders VM, Vitetta ES.
    J Immunol; 1987 Sep 01; 139(5):1734-8. PubMed ID: 2957434
    [Abstract] [Full Text] [Related]

  • 18. Specific activation of the prodrug mitomycin phosphate by a bispecific anti-CD30/anti-alkaline phosphatase monoclonal antibody.
    Sahin U, Hartmann F, Senter P, Pohl C, Engert A, Diehl V, Pfreundschuh M.
    Cancer Res; 1990 Nov 01; 50(21):6944-8. PubMed ID: 2170012
    [Abstract] [Full Text] [Related]

  • 19. The in vivo anti-tumor activity of immunotoxins containing two versus one deglycosylated ricin A chains.
    Ghetie V, Engert A, Schnell R, Vitetta ES.
    Cancer Lett; 1995 Nov 27; 98(1):97-101. PubMed ID: 8529213
    [Abstract] [Full Text] [Related]

  • 20. Successful treatment of disseminated human Hodgkin's disease in SCID mice with deglycosylated ricin A-chain immunotoxins.
    Winkler U, Gottstein C, Schön G, Kapp U, Wolf J, Hansmann ML, Bohlen H, Thorpe P, Diehl V, Engert A.
    Blood; 1994 Jan 15; 83(2):466-75. PubMed ID: 8286745
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.